References
- Non-Hodgkin’s Lymphomas. National Comprehensive Cancer Network; 2014 [cited 2015 Jun 18]. Available from: http://www.nccn.org/about/nhl.pdf.
- Adult Non-Hodgkin Lymphoma Treatment. National Cancer Institute; 2015 [cited 2015 Jun 19]. Available from: http://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq#section/_221.
- SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. National Cancer Institute; 2015 [cited 2015 Jun 18]. Available from: http://seer.cancer.gov/statfacts/html/nhl.html.
- Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin’s lymphoma in the United States during the first two years of treatment. Leuk Lymphoma 2006;47:1535–1544.
- Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–128.
- Annual Costs of Cancer Care – Cancer Prevalence and Cost of Care Projections. National Cancer Institute; 2010 [cited 2015 Jun 19]. Available from: http://costprojections.cancer.gov/annual.costs.html#f2.
- Wan Y, Gao X, Mehta S, et al. Indirect costs associated with metastatic breast cancer. J Med Econ. 2013;16:1169–1178.
- Fu AZ, Chen L, Sullivan SD, et al. Absenteeism and short-term disability associated with breast cancer. Breast Cancer Res Treat. 2011;130:235–242.
- Yaldo A, Seal B, Lage MJ. The cost of absenteeism and short-term disability associated with colorectal cancer: a case-control study. J Occup Environ Med. 2014;56:848–851.
- An Unhealthy America: The Economic Burden of Chronic Disease. Milken Institute; 2007 [cited 2015 Jun 19]. Available from: http://www.chronicdiseaseimpact.org/ebcd.taf?cat=disease&type=allcancer.
- Danielson E. White Paper: Health Research Data for the Real World: The MarketScan® Databases. Truven Health Analytics; 2014.
- Truven Health Analytics. Commercial claims and encounters medicare supplemental; 2011. White paper. Available from: http://truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf.
- Truven Health Analytics. Health and productivity management database; 2011. White paper. Available from: http://truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf.
- Current Employment Statistics – CES (National). Bureau of Labor Statistics; 2015; [cited 2015 Jun 19]. Available from: http://www.bls.gov/ces/#tables.
- Yurkovich M, Avina-Zubieta JA, Thomas J, et al. A systematic review identifies valid comorbidity indices derived from administrative health data. J Clin Epidemiol. 2015;68:3–14.
- Bureau of Labor Statistics. Consumer price index – all urban consumer, medical care. 2014; [cited 2014 Oct 11]. Available from: http://data.bls.gov/timeseries/CUUR0000SAM?output_view=pct_12mths.
- Hanly P, Pearce A, Sharp L. The cost of premature cancer-related mortality: a review and assessment of the evidence. Expert Rev Pharmacoecon Outcomes Res. 2014;14:355–377.
- American Cancer Society. Cancer facts & figures. Atlanta, GA: American Cancer Society; 2011. p. 1–55.
- Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst. 2008;100:1763–1770.
- Grunfeld E, Coyle D, Whelan T, et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ 2004;170:1795–1801.
- Palos GR, Mendoza TR, Liao K, et al. Caregiver symptom burden: the risk of caring for an underserved patient with advanced cancer. Cancer 2011;117:1070–1079.
- Caregiving in the U.S. 2015. National alliance for caregiving. AARP Public Policy institute. 2015;1–81. Available from: http://www.aarp.org/content/dam/aarp/ppi/2015/caregiving-in-the-united-states-2015-report-revised.pdf.
- Mitchell RJ, Bates P. Measuring health-related productivity loss. Popul Health Manage. 2011;14:93–98.
- Cancer.Net. Lymphoma – non-Hodgkin: subtypes. 2015; [cited 2015 Aug 2]. Available from: http://www.cancer.net/cancer-types/lymphoma-non-hodgkin/subtypes.
- Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563–2577.
- National Comprehensive Cancer Network. 20 Years of improving cancer care together – an NCCN roundtable discussion; [cited 2015 Sep 19]. Available from: http://www.nccn.org/about/news/newsinfo.aspx?NewsID=499.